Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31194569 | 0.83 | GAA (0.55) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8694634 | 0.81 | GAA (0.40) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL31194464 | 0.80 | MAPK1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20552007 | 0.79 | GAA (0.40) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL31194507 | 0.77 | GAA (0.40) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL11543788 | 0.74 | LMNA (0.41) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL11698200 | 0.72 | KMT2A (0.41) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1821874 | 0.72 | TSHR (0.47) | MAPTMEN1KMT2ALMNAKDM4E | |
| SCHEMBL31581849 | 0.72 | MAPT (0.39) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL16654250 | 0.71 | DYRK1A (0.37) | MAPTMEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902179-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20040147546-A1 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1396493-A1 | HETEROCYCLIC COMPOUNDS | Ajinomoto Co., Inc. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147546-A1 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | TNF, LITAF, NOD2 | MAPT 2891/4885MEN1 520/4885KMT2A 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.